contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


vicore-pharma-publishes-the-annual-report-for-2022

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Vicore Pharma operates in the pharmaceutical industry and focuses on the development of innovative treatments for pulmonary and cardiovascular diseases. The company researches new therapies that can improve patient outcomes and quality of life. The business is global with a primary presence in Europe and North America. Vicore Pharma was founded in 2000 and is headquartered in Gothenburg, Sweden.

Vicore Pharma Holding

Stockholm, April 5, 2023 –Vicore Pharma Holding AB (publ) (“Vicore” or “company”) unlocking the potential of a new class of drugs - angiotensin II type 2-receptor agonists (ATRAGs), today announced...

<div class="mfn-preamble"><p><strong>Stockholm, April 5, 2023 –Vicore Pharma Holding AB (publ) (“Vicore” or “company”) unlocking the potential of a new class of drugs - angiotensin II type 2-receptor agonists (ATRAGs), today announced the publication of the Annual Report for the financial year 2022.</strong></p></div><div class="mfn-body"><p>The Annual Report for the financial year 2022 is available on the company’s website: <a rel="noopener" href="https://vicorepharma.com/investors/financial-reports/">https://vicorepharma.com/investors/financial-reports/</a></p><p><strong>For further information, please contact:</strong><br>Hans Jeppsson, CFO, tel: +46 70&nbsp;553 14 65,&nbsp;<a rel="noopener" href="mailto:hans.jeppsson@vicorepharma.com">hans.jeppsson@vicorepharma.com</a>&nbsp;&nbsp;</p><p><strong>About Vicore Pharma Holding AB (publ)</strong><br><em>Vicore is an innovative Swedish clinical-stage pharmaceutical company dedicated to creating life changing treatments in diseases where the AT2 (angiotensin II type 2) receptor has a central role in stopping and reversing disease pathology. The company is establishing a portfolio in rare lung diseases including idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH). C21 is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG). Almee™ (an investigational medical device in clinical development) is a digital therapeutic (DTx) based on cognitive behavioral therapy (CBT) created to address the psychological impact of living with pulmonary fibrosis. Inhaled IMID is a new formulation and delivery route of thalidomide targeting the severe cough associated with IPF. With our unique expertise in the ATRAG biology we fuel our pipeline with several new assets with long patent life for a variety of diseases, some of which could be partnered while others can be taken to the market by Vicore itself.</em></p><p><em>The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see </em><em><a rel="noopener" href="http://www.vicorepharma.com/">www.vicorepharma.com</a></em><em>.</em></p></div><div class="mfn-footer mfn-regulatory mfn-regulatory-vpml"><p><em>This information is information that Vicore Pharma Holding is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-04-05 08:00 CEST.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/04f3c7c2-de0e-41fc-a822-1db99d570da7/vicore-annual-report-2022.pdf" class="mfn-primary">Vicore Annual Report 2022</a><br><a rel="noopener" href="https://storage.mfn.se/6d2491da-a097-49f0-ae24-96991018e77d/549300KTNBPTZLF01130-2022-12-31-en.zip">549300KTNBPTZLF01130-2022-12-31-en</a><br><a rel="noopener" href="https://storage.mfn.se/8c71c8c1-64a8-4cb1-bf65-b5f846ffc782/549300ktnbptzlf01130-2022-12-31-en-zip-viewer.html">549300KTNBPTZLF01130-2022-12-31-en.zip-viewer</a></p></div>